Neurology News and Research

Latest Neurology News and Research

GE Healthcare to develop wireless medical monitoring systems for patient care

In what would represent an important step forward in revolutionizing the way patients are monitored in the future, GE announced an initiative aimed to develop wireless medical monitoring systems, or body sensor networks (BSN), which would replace the traditional tangle of bedside cables used to capture a patient’s vital signs. GE’s vision for the systems would enable wireless monitoring from anywhere in the hospital—or even remotely from home.

2 Sep 2009

Advances in traumatic brain injury to be presented at the University of New Mexico

Dr. David Durham will present Advances in Traumatic Brain Injury at the University of New Mexico on Friday, September 4th to physicians and medical students in the departments of psychiatry and neurology.

2 Sep 2009

White matter hyperintensities could lead to permanent thinking problems

Elderly people with no memory or thinking problems are more likely to later develop thinking problems if they have a growing amount of "brain rust," or small areas of brain damage, according to a study published in the July 14, 2009, print issue of NeurologyÂ®, the medical journal of the American Academy of Neurology.

2 Sep 2009

Higher education levels associated with an earlier need for symptomatic treatment of Parkinson's disease

Individuals who have higher levels of education and who are more impaired by Parkinson's disease appear to require treatment for their symptoms earlier than do other patients, according to a report posted online today that will appear in the September print issue of Archives of Neurology, one of the JAMA/Archives journals.

2 Sep 2009

Pesticide beta-HCH in blood and Parkinson's disease are linked: UT Southwestern Medical Center

People with Parkinson's disease have significantly higher blood levels of a particular pesticide than healthy people or those with Alzheimer's disease, researchers at UT Southwestern Medical Center have found.

2 Sep 2009

Children suffering from chronic headache may outgrow the condition

Most children who suffer from chronic daily headache may outgrow the disabling condition, according to research published in the July 15, 2009, online issue of NeurologyÂ®, the medical journal of the American Academy of Neurology. Nearly 1.5 percent of middle school children are affected by chronic daily headache, which includes chronic migraines and tension-type headaches.

1 Sep 2009

Cigarettes and not Swedish snuff increase the risk of developing multiple sclerosis

While smoking cigarettes appears to significantly increase a person's risk of developing multiple sclerosis, using Swedish snuff does not, according to a study published in the September 1, 2009, print issue of Neurology®, the medical journal of the American Academy of Neurology.

1 Sep 2009

NASDAQ Stock Market issues noncompliance letter to Encorium Group

Encorium Group, Inc. (Nasdaq: ENCO), a full service multinational clinical research organization (CRO) conducting studies in over 30 countries for many of the world's leading pharmaceutical and biotechnology companies, today announced that on August 25, 2009, it received a letter from The NASDAQ Stock Market notifying the Company that, based on its Form 10-Q for the period ended June 30, 2009, NASDAQ has determined that the Company's stockholders' equity does not comply with the minimum $2.5 million stockholders' equity requirement for continued listing on The NASDAQ Capital Market as required by NASDAQ Marketplace Rule 5550(b)(1).

1 Sep 2009

Six-month period financial results released by Cannasat Therapeutics

Cannasat Therapeutics Inc., a clinical stage pharmaceutical company developing products to treat neurological disorders such as neuropathic pain and schizophrenia, today announced its results for the six months ended June 30, 2009. Unless specified otherwise, all amounts are in Canadian dollars.

1 Sep 2009

Cannasat Therapeutics announces completion of second tranche of prospectus offering

Cannasat Therapeutics Inc. ("Cannasat") (TSX VENTURE:CTH) is pleased to announce that it has completed a second tranche of its previously announced short form prospectus offering of units. Pursuant to the second tranche, Cannasat issued and sold 1,789,000 units at a price of $0.10 per unit raising gross proceeds of $178,900. This brings the total number of units sold under the prospectus offering to 9,298,500 for gross proceeds of $929,850.

1 Sep 2009

VAERS calls for reporting of GBS cases following 2009 H1N1 flu vaccination

The Centers for Disease Control and Prevention (CDC) and the American Academy of Neurology (AAN) are requesting neurologists to report any possible new cases of Guillain-Barr- syndrome (GBS) following 2009 H1N1 flu vaccination using the CDC and U. S. Food and Drug Administration Vaccine Adverse Event Reporting System (VAERS).

1 Sep 2009

AAO-HNSF to issue the first guideline for helping physicians manage dysphonia

The American Academy of Otolaryngology - Head and Neck Surgery Foundation (AAO-HNSF) will issue the first--and only--national clinical practice guideline to help healthcare practitioners identify and manage patients with hoarseness, also known as dysphonia. The guideline emphasizes evidence-based management of hoarseness by clinicians, and educates patients on the prevalence of this common vocal health issue.

1 Sep 2009

BrainStorm Cell Therapeutics partners with Protein Production to start production of clinical-grade stem cell therapeutic product

BrainStorm Cell Therapeutics Inc. (OTCBB:BCLI), a leading developer of adult stem cell technologies and therapeutics, announced today that it has entered into an agreement with Protein Production Services Ltd. (PPS), a leading manufacturing contractor, in order to start Good Manufacturing Practice (cGMP) production of its stem cell therapeutic product.

31 Aug 2009

Study reveals that downregulation of IRF-8 gene causes gum diseases, arthritis and osteoporosis

Investigators at Hospital for Special Surgery, collaborating with researchers from other institutions, have contributed to the discovery that a gene called interferon regulator factor-8 (IRF-8) is involved in the development of diseases such as periodontitis (gum disease), rheumatoid arthritis and osteoporosis. The study, which will be published online August 30, ahead of print, in the journal Nature Medicine, could lead to new treatments in the future.

31 Aug 2009

HIV subtype D infected patients more likely to develop dementia

Patients infected with a particular subtype of HIV, the virus that causes AIDS, are more likely to develop dementia than patients with other subtypes, a study led by Johns Hopkins researchers shows. The finding, reported in the September Clinical Infectious Diseases, is the first to demonstrate that the specific type of HIV has any effect on cognitive impairment, one of the most common complications of uncontrolled HIV infection.

28 Aug 2009

U.S. FDA agrees to the study design for cardiovascular outcomes trial of alogliptin

Takeda Pharmaceutical Company Limited ("Takeda") and Takeda Global Research & Development Center, Inc., a wholly owned United States (U.S.) subsidiary, today jointly announced that the latter has received notification that the U.S. Food and Drug Administration (FDA) has agreed to the study design for a cardiovascular (CV) outcomes trial titled EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome) for alogliptin, a selective dipeptidyl peptidase IV inhibitor under investigation for the treatment of type 2 diabetes as an adjunct to diet and exercise.

28 Aug 2009

Ipsen Group announces first-half 2009 financial results

The Board of Directors of Ipsen (Paris:IPN), chaired by Jean-Luc Bélingard, met on 27 August 2009 to review the Group’s results for the first half 2009, published today. The full 2009 half year financial report is available on the Group’s web site, www.ipsen.com, under the Regulated Information heading in the Investor Relations pages.

28 Aug 2009

Important development in the treatment of multiple sclerosis

A major step forward, with important implications for understanding how to reduce the severity of multiple sclerosis, has been made by scientists at the University of Bristol. The results are published online today in PNAS.

26 Aug 2009

Endo Pharmaceuticals gets exclusive rights to commercialize ProStrakan's FORTESTA in the U.S.

Endo Pharmaceuticals (Nasdaq: ENDP) today announced that it has signed an agreement with U.K.-based ProStrakan Group plc (LSE: PSK) for the exclusive right to commercialize FORTESTA(TM) (testosterone gel) 2 percent in the United States.

26 Aug 2009

Endo Pharmaceuticals Solutions announces the beginning of cash tender offer

Endo Pharmaceuticals announced today the commencement of a cash tender offer by its wholly-owned subsidiary, Endo Pharmaceuticals Solutions Inc., for any and all outstanding Ledgemont PhaRMA(SM) Secured 16% Notes due 2024 (the "Notes") of Ledgemont Royalty Sub LLC, Endo Pharmaceuticals Solutions Inc.'s wholly-owned subsidiary. The purpose of the tender offer is to acquire any and all Notes to reduce the consolidated interest expense of Endo.

26 Aug 2009

Neurology News and Research

Latest Neurology News and Research

GE Healthcare to develop wireless medical monitoring systems for patient care

Advances in traumatic brain injury to be presented at the University of New Mexico

White matter hyperintensities could lead to permanent thinking problems

Higher education levels associated with an earlier need for symptomatic treatment of Parkinson's disease

Pesticide beta-HCH in blood and Parkinson's disease are linked: UT Southwestern Medical Center

Children suffering from chronic headache may outgrow the condition

Cigarettes and not Swedish snuff increase the risk of developing multiple sclerosis

NASDAQ Stock Market issues noncompliance letter to Encorium Group

Six-month period financial results released by Cannasat Therapeutics

Cannasat Therapeutics announces completion of second tranche of prospectus offering

VAERS calls for reporting of GBS cases following 2009 H1N1 flu vaccination

AAO-HNSF to issue the first guideline for helping physicians manage dysphonia

BrainStorm Cell Therapeutics partners with Protein Production to start production of clinical-grade stem cell therapeutic product

Study reveals that downregulation of IRF-8 gene causes gum diseases, arthritis and osteoporosis

HIV subtype D infected patients more likely to develop dementia

U.S. FDA agrees to the study design for cardiovascular outcomes trial of alogliptin

Ipsen Group announces first-half 2009 financial results

Important development in the treatment of multiple sclerosis

Endo Pharmaceuticals gets exclusive rights to commercialize ProStrakan's FORTESTA in the U.S.

Endo Pharmaceuticals Solutions announces the beginning of cash tender offer

Neuroscience - Second Edition eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Neurology News and Research

Latest Neurology News and Research

Neuroscience - Second Edition eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in